Back to matchesWe found a matchYour institution may have rights to this item. Sign in to continue.TitleLong‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study.AuthorsGambacorti‐Passerini, Carlo; Orlov, Sergey; Zhang, Li; Braiteh, Fadi; Huang, Huiqiang; Esaki, Taito; Horibe, Keizo; Ahn, Jin‐Seok; Beck, Joseph T.; Edenfield, William Jeffrey; Shi, Yuankai; Taylor, Matthew; Tamura, Kenji; Van Tine, Brian A.; Wu, Shang‐Ju; Paolini, Jolanda; Selaru, Paulina; Kim, Tae MinPublicationAmerican Journal of Hematology, 2018, Vol 93, Issue 5, p607ISSN0361-8609Publication typeArticleDOI10.1002/ajh.25043